Sort   by:  
 Page size 
UnknownMicroRNA Expression-Based Model Indicates Event-Free Survival in Pediatric Acute Myeloid Leukemia.
Not available
S-EPMC5721230 | biostudies-literature
GenomicsNeuroblastoma relapse trio series from the AMC
The majority of neuroblastoma patients have tumors that initially respond to chemotherapy, but a large proportion of patients will experience therapy-resistant relapses. The molecular basis of this aggressive phenotype is unknown. Whole genome sequencing of 23 paired diagnostic and relapsed neurobla...
EGAS00001001183 | EGA
GenomicsCancer Genetic Markers of Susceptibility (CGEMS) Breast Cancer Genome-Wide Association Study (GWAS) - Primary Scan (Stage 1) - Nurses' Health Study

The Cancer Genetic Markers of Susceptibility (CGEMS) breast cancer genome-wide association study (GWAS) included genotyping 528,173 SNPs (Illumina HumanHap550) in 1,145 postmenopausal women of European ancestry with invasive breast cancer and 1,142 controls from the Nurses' Health Study (...

phs000147.v1.p1 | EGA
GenomicsCancer Genetic Markers of Susceptibility (CGEMS) Prostate Cancer Genome-Wide Association Study (GWAS) - Primary Scan (Stage 1) - PLCO Screening Trial

The Cancer Genetic Markers of Susceptibility (CGEMS) prostate cancer genome-wide association study (GWAS) included genotyping approximately 550,000 SNPs (Phase 1A with HumanHap300 and Phase 1B HumanHap240, both from Illumina, San Diego, CA) in 1,172 prostate cancer patients and 1,157 controls...

phs000207.v1.p1 | EGA
Genomicsena-DATASET-CURIE-LC-04-05-2015-16:47:47:270-89 - samples
Neuroblastoma, a clinically heterogeneous pediatric cancer, is characterized by distinct genomic profiles but few recurrent mutations. As neuroblastoma is expected to have high degree of genetic heterogeneity, study of neuroblastoma's clonal evolution with deep coverage whole-genome sequencing of di...
EGAD00001001356 | EGA
GenomicsInstitut Curie Neuroblastoma Whole Genome Sequencing Diagnosis Relapse
Neuroblastoma, a clinically heterogeneous pediatric cancer, is characterized by distinct genomic profiles but few recurrent mutations. As neuroblastoma is expected to have high degree of genetic heterogeneity, study of neuroblastoma's clonal evolution with deep coverage whole-genome sequencing of di...
EGAS00001001184 | EGA
GenomicsNational Cancer Institute (NCI) TARGET: Therapeutically Applicable Research to Generate Effective Treatments

The Therapeutically Applicable Research to Generate Effective Treatments (TARGET) Initiative seeks to accelerate research in novel marker and drug development, along with understanding the molecular basis of pediatric malignancy, through identification of genomic changes associated with the follo...

phs000218.v5.p1 | EGA
Genomicsena-DATASET-AMC-11-05-2015-14:58:16:693-185 - samples
The majority of neuroblastoma patients have tumors that initially respond to chemotherapy, but a large proportion of patients will experience therapy-resistant relapses. The molecular basis of this aggressive phenotype is unknown. Whole genome sequencing of 23 paired diagnostic and relapsed neurobla...
EGAD00001001360 | EGA
GenomicsInstitut Curie Neuroblastoma data access Committee
Data Access Committee EGAC00001000319
EGAC00001000319 | EGA
GenomicsAMC Dept. Oncogenomics
Data Access Committee EGAC00001000321
EGAC00001000321 | EGA
Sort   by:  
 Page size